Relapsed/Refractory HER2+ Metastatic Breast Cancer
This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
SABCS 2025: The Top 5 Takeaways for Breast Cancer Research
2
Novel Anti-BCMA Agent Shows Preliminary Responses in R/R Multiple Myeloma
3
PRO Data Support T-DXd Combo in HER2+ Advanced Breast Cancer
4
Majority of Breast Cancer Cohort Opts for Fertility Preservation Strategies
5